diabetes and may have a role in vascular diseases. It comes from either the diet (13) or is produced by the oxidation of choline (for a review, see Ref. 32) . A number of transporters with the ability to transport betaine have been identified (e.g., 7, 20, 57) . The present study focuses on the Na ϩ and Cl Ϫ dependent GABA/betaine acid transporter (BGT1; slc6a12). BGT1 was initially cloned (61) from Madin-Darby canine kidney (MDCK) cells, and most of the focus has been on its role in protecting kidney cells in highly hypertonic conditions (21) . BGT1 mRNA is present in the outer renal medulla and papilla (40) , where its expression is controlled by the transcription factor tonicity-responsive enhancer binding protein (TonEBP/NFAT5) in response to osmolarity changes (27, 40) . Most of these studies were done in vitro and were based on detection of mRNA. Little is known about BGT1 protein expression and cellular distribution in vivo. Furthermore, BGT1 mRNA has been detected in additional tissues, including the brain and liver (5, 9, 35, 53) , but the literature does not give a clear picture. In the liver, there is only indirect localization data (59) , based on functional assays, suggesting that liver BGT1 is expressed in nonparenchymal cells (Kupffer cells and sinusoidal endothelial cells) rather than hepatocytes. The situation is somewhat different in the brain. Here, BGT1 has been reported in brain endothelium (52) , in astrocyte and astrocytoma cultures (3, 6, 43, 47) , in pyramidal neurons (but not astrocytes) in rats (64) , and in neurons in Macaca fascicularis monkeys (63) . However, all the immunocytochemical studies appear to be based on antibodies, possibly the same antibody, to the carboxy terminal region of rat BGT1 despite sequence differences between species (Table 1) . Furthermore, knockout animals were not available as specificity controls, and this made it hard to distinguish true labeling from artifacts (for a discussion about antibody specificity, see Refs. 14, 23, and Ref. 25) . Nevertheless, the reported expression of BGT1 in the brain motivated pharmacological studies of BGT1 in seizure control (for a review, see Ref. 38 ), but when the experiments were repeated in genetically modified mice lacking the BGT1 gene, it was shown that this gene has no impact on the seizure susceptibility of adult mice (29) .
Here, we provide quantitative data on the distribution of BGT1 in vivo and the first immunocytochemical visualization of BGT1 protein in the liver and kidney. We show that BGT1 is expressed in hepatocytes and not in endothelium (neither in the liver nor in the brain or kidney), that it is present at high concentrations at the tip of the renal medulla, and that it is present in the leptomeninges, but hardly in the brain at all, ruling out a role in neurotransmitter activation. We also pro-vide quantitative data on the distribution of BHMT1 and SMIT1 mRNAs. Finally, we show that BGT1-deficient mice tolerate salt drinking as well as wild-type mice.
EXPERIMENTAL PROCEDURES
Materials. N,N= methylene bisacrylamide, acrylamide, ammonium persulfate, tetramethyleneethylenediamine (TEMED), and alkaline phosphatase substrates (nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate) were from Promega (Madison, WI). SDS of high purity (Ͼ99% C12 alkyl sulfate), bis(sulfosuccinimidyl)suberate, and SuperSignal West Dura were from Pierce (Rockford, IL), and electrophoresis equipment was from Hoefer Scientific Instruments (San Francisco, CA). Molecular mass markers for SDS-PAGE, biotinylated anti-rabbit Igs, and nitrocellulose sheets (0.22-m pores, 100% nitrocellulose) were from Amersham (Buckinghamshire, UK). Paraformaldehyde and glutaraldehyde were from TAAB (Reading, UK). DMEM/ F12 (1:1) with GlutaMAX, fetal bovine serum, nonessential amino acids, and Lipofectamine 2000 were from Invitrogen (Carlsbad, CA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Animals. All animal experimentations were carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC). Formal approval to conduct the experiments was obtained from the Animal Subjects Review Board of the Norwegian Governmental Institute of Public Health (Oslo, Norway). Care was taken to avoid suffering and minimize the number of experimental animals. Mice (BGT1-fKO) lacking the BGT1 (slc6a12) gene were housed, bred, and genotyped exactly as described previously (29) . These mice had a mixed C57BL6-129 background. All experiments were based on wild-type and knockout littermate pairs processed in parallel. When stated, pure C57BL6 (The Jackson Laboratory, Bar Harbor, ME) or CD1 (Charles River; Wilmington, MA) mice were used. The mice were 1-3 mo old when not stated otherwise. They were euthanized by cervical dislocation for biochemical measurements or by lethal (ip) injection of pentobarbital sodium before perfusion fixation for immunocytochemistry. New Zealand rabbits obtained from B&K Universal (Sollentuna, Sweden) were kept in the animal facility at the Institute of Basic Medical Sciences. Rabbits were immunized and bled as described (15), but they were injected subcutaneously rather than intracutaneously to minimize animal discomfort.
Antibodies to BGT1. Affinity-purified anti-peptide antibodies were prepared to mouse BGT1 (accession no. P31651) (33) as described (15) by immunizing rabbits with peptides corresponding to parts of the BGT1 protein as indicated ( Table 2 ). The ensuing antisera were affinity purified on columns with immobilized peptide. When rabbits were immunized with more than one peptide, antibodies to the individual peptides were separated (see Ref. 22) , resulting in more than one antibody from each rabbit (see Table 3 ). The C-terminal antibody (Ab) #590 (from rabbit 5B0130) and Ab#594 (from rabbit 5B0130) were used both for immunoblotting and for immunocytochemistry. Other antibodies, e.g., Ab#584 (from rabbit 5B0119) to the N-terminal peptide mBGT1(1-16) and Ab#323 (from rabbit 8D0156) to the C-terminal peptide BGT1 (599 -614) were used as controls. Alexa Fluor goat anti-rabbit 555 was from Molecular Probes (Eugene, OR). Rat antibodies to mouse CD31, which is also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), were from BD Bioscience Pharmingen (catalog no. 553370, lot 43370, San Diego, CA). Fluorescein-labeled Lotus tetragonolobus lectin (catalog no. FL-1321) and fluorescein-labeled Dolichos biflorus agglutinin lectin (catalog no. FL-1031-2) were from Vector Labs (Burlingame, CA).
RNA isolation, cDNA synthesis, and TaqMan assays. Portions of tissues (5-15 mg) were collected and immediately protected in RNAlater (Ambion) before homogenization and RNA extraction using RNeasy (Qiagen). The RNA concentration was quantified by using NanoDrop UV spectrometry (NanoDrop Technologies, Wilmington, DE). Two micrograms RNA were converted into cDNA by using a High Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, CA). Levels of mRNA were measured using TaqMan probes on a 7900HT Fast Real-Time PCR system (Applied Biosystems). The probes used to detect BGT1, GAPDH (as a control), TonEBP, SMIT1 (slc5a3), and BHMT1 were Mm00446665_m1/Mm00446675_ m1, Mm03302249_g1, Mm00467257_m1, Mm00444330_s1 and Mm04210521_g1, respectively.
BGT1 cDNA and transfection of cell cultures. HEK293 cells were grown at 37°C in 5% CO 2 in DMEM/F12 (1:1) with GlutaMAX supplemented with 10% fetal bovine serum and 100 M nonessential amino acids (Invitrogen). Cells were transiently transfected with BGT1 cDNA (33) (to which a C-terminal His-tag had been added) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. Transfected cells were harvested 48 h posttransfection by homogenization in ice-cold water with 5 mM EDTA and 1 mM PMSF. Following centrifugation (13,000 g, 10 min, 4°C), cellular The peptides were used for immunization and affinity purification of the antibodies. They represent parts of the BGT1 sequence (accession no. P31651) (33) and were synthesized as free acids or C-terminal amides as indicated. The N-terminal residues 1-16 [peptide name BGT1 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) ] are also present (as residues 15-30), the other known BGT1 splice variant of BGT1 (NP_598422; 9). Note that most rabbits were immunized with a mixture of two peptides (for details, see Ref. 15).
pellets were stored at Ϫ80°C until they were dissolved as described for tissue pellets below.
Tissue preparation for electrophoresis and immunoblotting. Tissue was homogenized in 10 -20 volumes of ice-cold water (containing 5 mM EDTA and 1 mM PMSF) and centrifuged (39,000 g, 20 min, 4°C). The supernatants from this centrifugation contained the watersoluble proteins and are hereafter referred to as the "supernatants." The pellets containing the water-insoluble proteins were subsequently solubilized in 1% (wt/vol) SDS in 10 mM sodium phosphate buffer with pH 7.4 (NaPi), briefly sonicated, and centrifuged (39,000 g, 20 min, 15°C). The supernatants from this last centrifugation are hereafter referred to as "pellets." The pellets and the supernatants were then subjected to SDS-PAGE and immunoblotted as described (24) .
Immunocytochemistry. Mice were perfusion fixed as described before (15). Briefly, they were given a lethal dose of pentobarbital sodium and after cessation of all reflexes, they were perfusion fixed in 4% formaldehyde in NaPi with or without 0.1% glutaraldehyde as stated for 5 min. The relevant tissues were collected and immersed in fixative for ϳ1 h at room temperature. Sections were cut from the fixed unfrozen tissue (thickness 50 m) using a Vibratome 1000 plus (Vibratome, Bannockburn, UK) or cryoprotected with sucrose and cut using a Cryotome Microm HM450 (thickness 40 m, Thermo Fisher Scientific). All experiments were performed using wild-type and BGT1 knockout littermate pairs processed in parallel to maximize the probability that differences between wild-type and knockout mice were due to BGT1 and not to other factors such as fixation time, animal age, or rearing conditions.
Immunoperoxidase labeling was done as previously described (24) . The sections were treated (5 min) with 1% hydrogen peroxide in 0.1 M NaPi to inactivate endogenous peroxidase and then treated (30 min) with 1 M ethanolamine in 0.1 M NaPi. After being washed in PBS (135 mM NaCl in 10 mM NaPi), the sections were incubated for 1 h in TBS (300 mM NaCl in 100 mM Tris·HCl buffer, pH 7.4) containing 10% newborn calf serum (or when stated, 1% nonfat milk). Then, they were incubated with primary antibodies overnight, followed by biotinylated donkey anti-rabbit Ig (1:100) and streptavidin-biotinylated horseradish peroxidase complex (1:100). The sections were examined and photographed on a Zeiss Axioskop 2 plus equipped with an AxioCam MRc r1.2 camera (Zeiss, Jena, Germany).
For immunofluorescent labeling, the sections were rinsed (3 ϫ 5 min) in TBST (TBS with 0.5% Triton X-100), treated with 1 M ethanolamine in 0.1 M sodium phosphate buffer pH 7.4 for 30 min, washed in TBST, incubated (1 h) in TBST containing 10% newborn calf serum and 3% bovine serum albumin, followed by incubation with primary antibodies and finally with secondary antibodies (Alexa Fluor goat anti-rabbit 555, Molecular Probes) diluted 1:1,000. For double labeling, fluorescently labeled lectins to renal collecting ducts (fluorescein-labeled D. biflorus agglutinin) or renal proximal tubules (fluorescein-labeled L. tetragonolobus lectin) (45) were diluted to 1:300 and added to the secondary antibody solutions. The sections were observed in a Zeiss Axioplan 2 microscope equipped with a Zeiss LSM 5 Pascal confocal scanner head (Zeiss). Pinhole size was ϳ1 area unit, optimized for each wavelength to ensure confocality. Excitation wavelengths were 488 and 555 with corresponding emission wavelengths at 520 and 568 nm.
Salt drinking. An increase in renal medullary osmolarity was achieved by 48 h of salt drinking. Mice were given unrestricted access to 2.5% sodium chloride solution for drinking, while control mice drank water (17, 55) . Samples of blood and bladder urine were obtained under anesthesia before removal of tissues. Osmolarity in a 10-l sample of plasma or urine was measured by the vapor pressure method in a Vapro osmometer (Wescor, Logan, UT) after calibration with known standards. Using this protocol in preliminary experiments, the average consumption of sodium chloride solution over 48 h was 18 ml/mouse compared with water consumption of 10 ml/ mouse. As expected, urine osmolarity increased from 1,319 (n ϭ 2) in controls to 2,908 mosmol/kgH 2O (n ϭ 3) after salt drinking, but plasma osmolarity was unchanged consistent with renal compensation for the salt load.
RESULTS

Distribution of BGT1 and BHMT1 mRNAs in mouse tissues.
We have previously shown that the brain levels of BGT1 mRNA were orders of magnitude lower than those of GABA A and B) and betaine:homocysteine S-methyltransferase (BHMT1; C and D) in young adult C57BL6 mice. Note that both BGT1 and BHMT1 mRNAs are particularly abundant in the liver. Also note that BGT1 mRNA is present in the renal medulla (B), while BHMT1 is present in the cortex (D). The mRNA levels were measured using TaqMan real-time PCR analysis. BGT1 mRNA was detected with probe Mm00446665_m1, while BHMT1 mRNA was detected with the Mm04210521_g1 probe. The results in A and C are expressed as percentage of the levels in the liver, while the highest values were defined as 100% in B and D. Values are means Ϯ SE (n ϭ 3 mice). Note that kidney samples were thin slices from the middle part of kidneys containing both the renal cortex and renal medulla, but not including the very tip of the medulla where the BGT1 levels are the highest.
transporter 1 (29) , and thereby so low that it was natural to ask whether BGT1 is expressed more in other organs. This is in fact suggested by Northern blot analysis (35) . We therefore quantified BGT1 mRNA in several tissues (Fig. 1A) by TaqMan real-time PCR using the same BGT1 probe as we have previously verified (Mm00446665_m1; 29). In agreement with López-Corcuera and coworkers (35), we found the highest BGT1 levels in the liver followed by the renal medulla. The mRNA levels in the liver are ϳ30 times higher than those in the cerebellum. BGT1 mRNA is virtually absent in the renal cortex (Fig. 1B) , small intestine (Fig. 1A) , colon (not shown), and skeletal muscle (not shown).
In addition to the role as one of several osmolytes in the kidney medulla, betaine is a methyl donor whereby betaine is converted to methionine in a process catalyzed by BHMT1. In agreement with enzyme activity data (39), we find the highest Note that this blot has been developed for a long time after lanes 1 and 3 reached saturation before brain and kidney BGT1 became visible. Also note that the neocortical surface (lane 11) gives a stronger signal than whole neocortex (lane 9). No BGT1 signal was detected in neocortical samples. Furthermore, the electrophoretic mobility differs somewhat between organs. Lanes 1 and 2 contained 20 g protein each, while the rest contained 30 g of protein each. The blot was developed with the C-terminal BGT1 antibody (Ab) #590 (0.5 g/ml), and bound antibodies were detected using alkaline phosphatase-conjugated secondary antibodies and alkaline phosphatase substrates. This detection system has a relatively low contrast. Tissue from WT and KO mice are from littermates processed in parallel. DF, dye front. B: another blot showing WT cerebellum (15 and 30 g/lane as indicated) compared with various mixtures of wild-type liver and KO cerebellum where the total protein amounts are kept constant at 30 g/lane. The asterisk represents 30 g of liver KO. The numbers represent micrograms of water-insoluble proteins (pellet). The blot was developed with enhanced chemiluminescence. Two exposure times (the same immunoblot) are shown (20 and 1,000 s). Note that WT liver gave a visible signal at 5 g already at 20 s, while long exposure times were required to see cerebellar BGT1 (indicated by arrowheads). Also note that 30 g of cerebellum KO gives no signal. Note that 30 g of WT cerebellum gives a weaker signal than 1 g of WT liver. The levels of BGT1 protein in the cerebellum is thereby much lower than those in the liver in agreement with the mRNA data (Fig. 1) . BHMT1 mRNA levels in the liver (Fig. 1C) . In the kidney, the distribution was the opposite of that of BGT1. BHMT1 was predominantly in the cortex and at low levels in the medulla (Fig. 1D) . No differences in BHMT1 mRNA levels between wild-type and BGT1 knockout mice were noted (data from two wild-type littermate pairs; not shown).
Detection of BGT1 protein by immunoblotting. Antibodies were raised against synthetic peptides and screened by Western blotting of whole tissue (brain and kidney) directly homogenized in SDS as we have successfully done before (15). However, no signal was obtained. This could be due to low BGT1 expression, but whole-cell SDS-extracts from BGT1-transfected HEK293 cells were also immunonegative (data not shown). Initially, it was therefore concluded that none of the antibodies recognized the native protein, but this lack of success was puzzling considering that several peptides and several rabbits were used. Based on experiences with glutamate transporters (Ref. 16 and Holmseth S and Danbolt NC, unpublished observations), we asked whether water-soluble proteins could compete with the binding of membrane proteins like BGT1 to the blotting membranes and thereby interfere with the detection on Western blots. To test this, water-soluble and water-insoluble proteins were separated from each other. Once the water-soluble proteins were removed, most of the antibodies (Table 3 ) gave strong signals with both transfected cells and liver extracts. Figure 2 shows a blot developed with Ab#590. In agreement with the mRNA data (Fig. 1) , the strongest BGT1 labeling was obtained with extracts from wild-type liver (Fig. 2A, lane 3) . Extracts from whole kidney gave weak BGT1 signals (lane 7). This antibody (Ab#590) also labeled a band at ϳ200 kDa, which does not represent BGT1 because it was present in the kidney samples from the BGT1 knockout mice (lane 8) and because it was not recognized by other BGT1 antibodies (not shown). Note that this crossreactivity did not affect the immunocytochemistry (see below), in agreement with the notion that not all epitopes present on Western blots are available in sections and vice versa (for a discussion, see Ref. 25) .
When the external surface of the neocortex was scraped off to give samples enriched with respect to pia mater, no signal was detected in the remaining neocortex (Fig. 2A, lane 9) , while a weak BGT1 signal was detected in the surface tissue ( Fig. 2A, lane 11) . Extracts from the cerebellum also gave weak BGT1 signals (Fig. 2A, lane 13) , but this may in part be due to a larger surface/volume ratio. Extracts from the spleen, testis, and intestine gave no signal (data not shown). Tissue from knockout mice was run as controls ( Fig. 2A, lanes 6, 8,  10, 12 and 14) . When (Fig. 2B) extracts from the cerebellum (15 and 30 g protein/lane) were compared with mixtures of wild-type liver extracts and knockout cerebellum extracts (total amounts were kept constant at 30 g protein/lane), it was clear that there is slightly more BGT1 in 1 g of liver protein than in 30 g of cerebellar protein (Fig. 2B) . The reason it was decided to dilute liver extracts in knockout cerebellum extracts was to make the samples as comparable as possible so that we could rule out the possibility that the cerebellum contains proteins interfering with BGT1 binding to nitrocellulose. This was a concern as explained above.
The BGT1 levels in the cerebellum seemed slightly higher soon after birth than in the adults (Fig. 2C) . The proportions between BGT1 in the liver and cerebellum were similar in other mouse strains (pure C57BL6 and CD1), suggesting that the low levels observed here are not strain specific (data not shown).
Because BGT1 mRNA has been reported to be in the kidney medulla (e.g., Ref. 40) , tissue from the medulla and cortex were collected separately for Western blot analysis (Fig. 3) . In agreement, BGT1 protein was readily detected in the medulla and not in the cortex. However, even though BGT1 is concentrated in the medulla, the concentration in the liver is still higher (compare lanes 2 and 4 in Fig. 3A) , possibly with the exception of the tip of the papilla (see below).
Immunocytochemical localization of BGT1 protein. In agreement with the above results (Figs. 1-3 ), BGT1 protein was readily detected in the liver (Fig. 4) , where it was expressed in hepatocytes throughout the organ (Figs. 4 and 5) . The highest labeling intensities were observed in the parts of the plasma membranes facing the sinusoids (Figs. 4, C and E, and 5B), while the membranes facing other hepatocytes were more weakly labeled. The endothelium was not labeled (Fig.  5D) , showing that BGT1 is not expressed in the endothelium.
In the kidney, the labeling was in the medulla and not in the renal cortex (Figs. 6 and 7) . The highest concentration was in the tip of the renal papilla (Fig. 6G ), but there was also BGT1 in the outer parts of the medulla, albeit at far lower levels. Confocal microscopy ( Fig. 7) further showed that most of the BGT1 protein is in the basolateral membrane, in both medullary thick ascending tubules (MTAL) and in collecting ducts. However, in MTAL there is also BGT1 in the cytoplasm (Fig.  7A) . Because BGT1 has been assumed to play a role in the macula densa in rats (8), we specifically looked for labeling here as well as in the juxtaglomerular apparatus. However, no labeling was observed in young adult mice (data not shown). Figure 8 represents a schematic summary of the findings. , and bound antibodies were detected using alkaline phosphataseconjugated secondary antibodies and alkaline phosphatase substrates. Also note that the WT liver sample gave a much stronger signal.
Although immunoblots showed that BGT1 is expressed at low overall levels in brain parenchyma, the possibility existed that a subpopulation of brain cells could express BGT1 at high levels. In agreement with the immunoblots (Fig. 2A, lane 11) , we confirmed BGT1 labeling at the brain surface (Fig. 9) . There was no colocalization with glial glutamate transporters, confirming that the labeling is not due to glia limitans (data not shown). Also, the cells lining the brain ventricles (the ependymal cells), including choroid plexus and tanycytes, were unlabeled. No labeling was detected in brain tissue proper (Fig. 9) unless the antibodies were used in such high concentrations that they also labeled knockout tissue. We could therefore not confirm a report (63) describing neuronal expression of BGT1 in monkeys. Furthermore, there was no endothelial labeling (Fig. 9) , and we therefore also do not confirm the reported presence of BGT1 in the blood-brain barrier (e.g., Ref. 52). It should, however, be mentioned that one of our anti-BGT1 antibodies (Ab#323) did label endothelium in the kidney, but this labeling was also seen in the knockout (not shown here, but see Ref. 25) , and it was concluded that this antibody recognized something else in addition to BGT1. As reported before, highly specific cross-reactivity with seemingly unrelated molecules is common (e.g., Refs. 22 and 25).
BGT1 was upregulated in wild-type mice after 48 h of salt drinking, but also knockout mice maintained normal plasma osmolarity. Osmotic stress in the renal medulla was induced by letting mice drink 2.5% sodium chloride for 48 h. This caused upregulation of the mRNAs encoding TonEBP, SMIT1, and BGT1 in the kidney medulla of wild-type mice (Fig. 10, A-C) compared with water-drinking control mice. Salt drinking also increased BGT1 protein levels (Fig. 10D ) in wild-type mice but did not cause redistribution of BGT1 in the kidney (Fig. 11) . In contrast, only small changes in mRNA levels were observed in the liver (Fig. 10A) , and no changes in protein levels could be detected by immunoblot- ting (Fig. 10D) . Furthermore, there were no changes in the cerebellar samples (Fig. 10, A-C) . The reason the changes in the liver and in the cerebellum were so small may be that the kidneys were able to keep plasma osmolarity at normal levels. The urine osmolarity was more than doubled by salt drinking (see EXPERIMENTAL PROCEDURES). In contrast, plasma osmolarity did not change in either wild-type or knockout mice. The plasma osmolarity values (means Ϯ SE, n ϭ 3 mice) for salt-drinking and water-drinking wild-type mice were, respectively, 273 Ϯ 8.1 and 292 Ϯ 15 mosmol/ kgH 2 O. The corresponding values for BGT1-deficient mice were 287 Ϯ 8.4 and 275 Ϯ 8.4 mosmol/kgH 2 O. It is notable that the BGT1 knockout mice showed no marked ill effects after 72 h of 2% sodium chloride drinking, possibly because other osmolyte transporters, e.g., SMIT1 (slc5a3), in the renal medulla, were able to compensate for lack of BGT1. SMIT1 has a broader distribution (Fig. 10E ) than BGT1. The highest SMIT1 levels were in the renal medulla, while liver levels were low.
DISCUSSION
BGT1 is predominantly a liver protein.
As shown here, the distribution of BGT1 is quite restricted. The highest BGT1 concentrations ( Fig. 1) are in the liver, and when the organ size is taken into consideration, it follows that the overwhelming majority of BGT1 molecules are in the liver. Furthermore, considering the ease by which BGT1 protein could be detected, it seems that the total amounts of BGT1 protein are substantial and that the liver thereby has a large capacity for taking up betaine.
BGT1 is expressed in hepatocytes and targeted to the plasma membranes facing blood plasma. This location makes BGT1 ideally suited to take up betaine from the blood and thereby to supply betaine to hepatocytes. Hepatocytes express BHMT1, which is the only known enzyme that can metabolize betaine. In principle, BGT1 may also take up GABA, but this is probably not an important function considering that BGT1 has lower affinity for GABA than GABA transporter 2 (GAT2; slc6a13) (26) , which is also found in the liver (Ref. 20 and Zhou Y and Danbolt NC, unpublished observations). To our knowledge, BGT1 is the only transporter that is both predominantly expressed in the liver and able to transport betaine. The sodium/imino acid transporter (SIT1; slc6a20) (28, 51) and the proton-dependent amino acid cotransporter (PAT1; slc36a1) (4, 7) are present in the intestine and kidney, but not in the liver, while organic anion transporter 9 (oat9S) (57) and the carnitine transporter (OCTN2, slc22a5) (54) are present in the liver at low concentrations (20, 57) , being mostly expressed elsewhere, including the kidney. At present, it is not known how the levels of BGT1 compare to those of OCNT2 and oat9S. Nevertheless, non-BGT1 transporters may provide sufficient redundancy to explain the apparent lack of phenotype of the BGT1 knockout mice. The BGT1 knockout mice are healthy under nonchallenging rearing conditions (29) but have not yet been tested in situations where the demand for betaine is increased. Betaine is believed to have a therapeutic potential for treatment of mild hyperhomocysteinemia (49), nonalcoholic steatohepatitis (58, 1), and alcohol-induced liver damage. This therapeutic potential probably relies on betaine uptake, and the BGT1-knockout mice will be good models for testing this.
The main role of BGT1 in the kidney is probably in the tip of the papilla. There are several betaine-transporting carrier proteins in the brush border of proximal tubules (e.g., Refs. 4, 7, 51, 57). These transporters, slc6a20 in particular (44) , are likely to be those responsible for reabsorption of betaine in the glomerular filtrate. The betaine taken up by them may be the betaine that the kidney can metabolize, considering that there is BHMT1 in the renal cortex (Fig. 11) in agreement with previous studies (18, 39) . In contrast, BGT1 expression is restricted to the medulla and the BGT1 protein is targeted to the basolateral membranes (Fig. 7) . This supports the notion that BGT1 enables medullary cells to take up betaine from the blood (34, 41) rather than from the glomerular filtrate. As BHMT1 is the only known enzyme able to metabolize betaine, the low levels of BHMT1 in the medulla (Fig. 11) suggest that betaine acts predominantly as an osmolyte at this location, as previously assumed (2) . Thus our data agree nicely with the literature (10) . This supports the counteracting-osmolyte hypothesis that the addition of the methylamine betaine provides protection from the inhibitory effects of urea (62) . Neverthe- less, the extreme concentration of BGT1 at the tip of the papilla was a surprise and makes it legitimate to wonder whether betaine may be especially relevant for the prevention of renal papillary necrosis as it has been shown that loss of TonEBP causes lack of expression of several genes (including BGT1) and renal atrophy (36) . However, as pointed out above, BGT1-deficient mice are apparently healthy and survive to a high age under nonchallenging conditions (29) . In fact, as shown here, the BGT1-deficient mice tolerate salt drinking well and manage to maintain normal plasma osmolarity. This does suggest that there is a redundancy in that other osmolytes (e.g., sorbitol and myo-inositol) may be able to compensate for a loss of BGT1 function (42) . Myo-inositol is taken up by SMIT1, while sorbitol is synthesized from glucose by aldose reductase. Both SMIT1 (40) and aldose reductase (40, 56) are concentrated in the medulla and have been shown to protect cell cultures derived from the inner medulla (2, 56) . However, reduction of sorbitol levels by inhibition of aldose reductase does not appear to cause serious kidney damage (60) . A possible explanation could be that betaine (42) or myo-inositol can substitute for sorbitol. We therefore propose the hypothesis that the true importance of BGT1, aldose reductase, and SMIT1 will not be apparent unless two or all of them are put out of action at the same time. This remains to be tested, however, as there may be even more protective mechanisms.
BGT1 is unlikely to contribute to inactivation of GABA in the brain. The results presented here show low overall levels of BGT1 protein in the young adult brain and that the small amounts of BGT1 that are expressed (Fig. 2B ) are found at the surface rather than in brain tissue proper ( Figs. 2A and 9 ). These conclusions are in agreement with data on mRNA levels (19, 29, 37) . Furthermore, the absence of BGT1 in the choroid plexus is in agreement with the substrate selectivity of transport across the blood-brain barrier (46) . In the present report, we do not address the question of whether BGT1 plays a role during development, but we confirm that BGT1 is present at somewhat higher levels (although still low) in the developing cerebellum (Fig. 2C) (19) . This may explain why BGT1 has been detected in astrocyte cultures (e.g., Ref. 43 ) because primary cultures of astroglia, prepared from neonatal rodent brain, are apparently derived from a small, unidentified population of proliferating glial precursor cells that express several astrocyte markers, but which appear to have an immature or reactive phenotype and are thereby of an unclear relationship to those of mature astrocytes in the postnatal and adult brain (10) .
The preferential expression at the surface implies that the concentration of BGT1 around synapses is exceedingly low in young adult mice. This is important because numbers matter as cotransport is a relatively slow process requiring tens of milliseconds for completion of a full transport cycle. Submillisecond transmitter removal thereby requires more vacant binding sites (transporter molecules) than released neurotransmitter molecules because neurotransmitters diffuse quickly out of the synaptic cleft on a low-microsecond timescale until they bind to transporters and are removed (e.g., Refs. 12, 31, 48). Thus, unless there are more transporters in the immediate vicinity of each synapse than released GABA molecules (3,000 -5,000), GABA molecules will then pass by all occupied transporters, diffusing multiple synapse diameters away by the time the occupied transporters have completed one transport cycle. The high numbers of transporters needed at each synapse and the fact that there is about one nanomole of nerve terminals (ϳ10 15 ) per liter of brain tissue (the neuropil part of it; see section 3.2.1 in Ref. 14) explain why GAT1 (11) and the GLT1 glutamate transporter (30) are expressed at such high levels in the brain. Furthermore, because BGT1 is expressed at low levels, and also has lower affinity for GABA (26) , it follows that BGT1 is unable to influence extracellular GABA levels. On this background, it is not surprising that BGT1-knockout mice have normal seizure thresholds (29) .
BGT1 in the leptomeninges. The highly selective expression of BGT1 in the leptomeninges is remarkable, implying that BGT1 concentration is very high. However, because the low overall amount of BGT1 protein at this location is small, it seems unlikely that BGT1-mediated transport ca- The sections in A and B were labeled using peroxidase as a reporter, while the sections in C and D were double labeled with anti-BGT1 antibody (Ab#590; red; 1 g/ml) and anti-CD31 (green; 0.5 g/ml; endothelial marker) and then mounted in DAPI mounting medium, resulting in blue nuclei. Note that there is BGT1 labeling of the leptomeninges in the WT animals (A and C) and not in the KO animals (B and D). Furthermore, some labeling of neuronal cell bodies in sections from WT mouse (A, arrowhead) also appears in sections from the KO mice (B, arrowhead). Fixative: 4% formaldehyde in 0.1 M NaPi. Scale bars ϭ 20 m. Fig. 10 . Upregulation of BGT1, sodium-myo-inositol cotransporter 1 (SMIT1), and tonicity-responsive enhancer binding protein (TonEBP) in mouse kidney medulla from WT and BGT1 KO mice following 48 h of either 2.5% NaCl drinking (S) or water drinking (W). A-C: expression levels of mRNA encoding BGT1, SMIT1, and TonEBP as indicated. Note that all the 3 mRNAs were strongly upregulated in kidney medulla and that there were no changes in the cerebellum, but possibly a small upregulation of TonEBP and BGT1 in the liver. Values are means Ϯ SE (n ϭ 3 mice). Note that this figure compares the effect of salt drinking within each organ. Thus kidney, liver, and cerebellum from water-drinking WT animals were all defined as 100%. To compare different organs with each other, see Figs. 1A and 10E. D: BGT1 protein in mouse kidney medulla and liver after sodium chloride drinking (water drinking as control). Tissues from 3 pairs of WT littermate mice were collected: 15 g water-insoluble protein was loaded in kidney medulla lanes, while 10 g protein was loaded in liver lanes. The blot was developed with the anti-BGT1 antibody (Ab#590; 0.5 g/ml), and bound antibodies were detected using chemiluminescence. The blot shows 3 samples from salt-drinking and 2 of the water-drinking WT mice as well as 1 of the water-drinking KO mice. E: distribution of SMIT1 mRNA in young adult C57BL6 mice was measured with TaqMan real-time PCR analysis using the Mm00444330_s1 probe. Values are means Ϯ SE (n ϭ 3 mice). Note that SMIT1 is predominantly expressed in the kidney but also that significant levels are found in several organs, with the liver and duodenum as the exceptions.
pacity is large enough to have any direct influence on the brain itself. Therefore, BGT1 is more likely to play a local role in these cells.
Conclusions. The physiological roles that a protein can play are limited not only by the protein properties but also by both its localization and its concentration. Here, we provide the first visualization of BGT1 protein in the liver and kidney, and we also provide the first (semi)quantitative data on mRNA and protein levels. Because we have used several BGT1 antibodies and BGT1 knockout mice as negative controls, we have been able to validate the measurements better than has been possible before. We have addressed the following topics.
1) The low level of brain BGT1 and its confinement to the leptomeninges suggest that BGT1 is not important for the blood-brain barrier and does not play a role in the inactivation of transmitter GABA. This explains why no difference was found between BGT1 wild-type and knockout mice in several seizure threshold models (29) .
2) We confirm that BGT1 is present in the renal medulla and that it is upregulated in response to osmotic stress, but we also show that BGT1-deficient mice tolerate osmotic stress well, suggesting the existence of compensatory mechanisms. The localization data presented here predict that non-BGT1 transporters in the proximal tubule (60) prevent filtered betaine from being lost in the urine, while BGT1 in medullary nephron segments accumulates betaine from the vascular system.
3) We show that most of the BGT1 protein is present in hepatocytes. Further studies will determine the significance of liver BGT1. Betaine acts as a methyl donor in the liver, participating in the methionine cycle, and, for this reason, it is used to reduce plasma homocysteine (49) and to treat nonalcoholic fatty liver disease (1, 58) .
